LONG-TERM MAINTENANCE THERAPY WITH CYCLOSPORINE AND POSTTREATMENT SURVEY IN SEVERE PSORIASIS - RESULTS OF A MULTICENTER STUDY

被引：51

作者：

MROWIETZ, U ^{[1
]}

FARBER, L ^{[1
]}

HENNEICKEVONZEPELIN, HH ^{[1
]}

BACHMANN, H ^{[1
]}

WELZEL, D ^{[1
]}

CHRISTOPHERS, E ^{[1
]}

HUMS ^{[1
]}

PRIFERT ^{[1
]}

ALBRECHT ^{[1
]}

BORCHERS ^{[1
]}

CZARNETZKI ^{[1
]}

KNOLL ^{[1
]}

MEFFERT ^{[1
]}

STOJANOW ^{[1
]}

ALTMEYER ^{[1
]}

ELGAMMAL ^{[1
]}

KREYSEL ^{[1
]}

LINDENBLATT ^{[1
]}

TRONNIER ^{[1
]}

BENDER ^{[1
]}

BARTH ^{[1
]}

HUBNER ^{[1
]}

SCHOPF ^{[1
]}

KERN ^{[1
]}

MEYER ^{[1
]}

FELGENTRAGER ^{[1
]}

TAUBE ^{[1
]}

FIEDLER ^{[1
]}

MENSING ^{[1
]}

RADLOFF ^{[1
]}

KNOPF ^{[1
]}

BARTA ^{[1
]}

PETRES ^{[1
]}

FULLER ^{[1
]}

CHRISTOPHERS ^{[1
]}

MROWIETZ ^{[1
]}

WASSILEW ^{[1
]}

HORN ^{[1
]}

SCHLENZKA ^{[1
]}

PESCHLOW ^{[1
]}

JUNG ^{[1
]}

WEISS ^{[1
]}

FRIEDERICH ^{[1
]}

GEORGI ^{[1
]}

BORELLI ^{[1
]}

HUBER ^{[1
]}

BRAUNFALCO ^{[1
]}

BERGNER ^{[1
]}

BROCKER ^{[1
]}

OTT ^{[1
]}

机构：

[1] SANDOZ AG,DEPT CLIN RES,NURNBERG,GERMANY

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1995年 / 33卷 / 03期

关键词：

D O I：

10.1016/0190-9622(95)91393-9

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Although cyclosporine has been found to be effective therapy for severe psoriasis, only limited data exist about efficacy and safety during long-term treatment with a low-dose regimen. Furthermore, little is known about the course of psoriasis after drug withdrawal. Objective: Our purpose was to assess the results of long-term therapy with cyclosporine for severe psoriasis with particular regard to efficacy and safety, as well as the disease course after stopping treatment. Methods: A multicenter study of 217 patients treated with 1.25, 2.5, or 5.0 mg/kg per day of cyclosporine was performed. Duration of treatment ranged from 6 to 30 months followed by a posttreatment period of 3 months. Efficacy was assessed by the Psoriasis Area and Severity Index and safety was monitored by clinical and laboratory investigations. Results: Patients with severe psoriasis showing a reduction in the Psoriasis Area and Severity Index of 75% with their individual dose of cyclosporine maintained clinical improvement during continuous maintenance therapy. Newly occurring side effects were less frequent during the maintenance phase than in the induction phase. After withdrawal of cyclosporine, worsening of psoriasis requiring antipsoriatic therapy was seen in about half of the patients. Conclusion: Cyclosporine is effective for long-term therapy for severe psoriasis and does not lead to severe deterioration of the disease after drug withdrawal.

引用

页码：470 / 475

页数：6

共 20 条

[1] CYCLOSPORINE IN PSORIASIS - A MULTICENTER DOSE-FINDING STUDY IN SEVERE PLAQUE PSORIASIS [J].

CHRISTOPHERS, E ;

MROWIETZ, U ;

HENNEICKE, HH ;

FARBER, L ;

WELZEL, D ;

HUMS ;

PRIFERT ;

ALBRECHT ;

BORCHERS ;

CZARNETZKI ;

KOLL ;

MEFFERT ;

STOJANOW ;

ALTMEYER ;

ELGAMMAL ;

KREYSEL ;

LINDENBLATT ;

TRONNIER ;

BENDER ;

BARTH ;

HUBNER ;

SCHOPF ;

KERN ;

MEYER ;

FELGENTRAGER ;

TAUBE ;

FIEDLER ;

MENSING ;

RADLOFF ;

KNOPF ;

BARTA ;

PETRES ;

FULLER ;

CHRISTOPHERS ;

MROWIETZ ;

WASSILEW ;

HORN ;

SCHLENZKA ;

PESCHLOW ;

JUNG ;

WEISS ;

FRIEDERICH ;

GEORGI ;

BORELLI ;

HUBER ;

BRAUNFALCO ;

BERGNER ;

BROCKER ;

OTT ;

KOCH .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (01) :86-90

[2]

DERIE MA, 1993, BRIT J DERMATOL, V123, P347

[3] CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].

ELLIS, CN ;

FRADIN, MS ;

MESSANA, JM ;

BROWN, MD ;

SIEGEL, MT ;

HARTLEY, AH ;

ROCHER, LL ;

WHEELER, S ;

HAMILTON, TA ;

PARISH, TG ;

ELLISMADU, M ;

DUELL, E ;

ANNESLEY, TM ;

COOPER, KD ;

VOORHEES, JJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284

[4] CYCLOSPORINE MONITORING IN PSORIASIS [J].

FEUTREN, G ;

FRIEND, D ;

TIMONEN, P ;

LABURTE, C .

LANCET, 1990, 335 (8693) :866-867

[5] RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].

FEUTREN, G ;

MIHATSCH, MJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660

[6] PREDICTIVE VALUE OF CYCLOSPORINE-A LEVEL FOR EFFICACY OR RENAL DYSFUNCTION IN PSORIASIS [J].

FEUTREN, G ;

FRIEND, D ;

TIMONEN, P ;

BARNES, A ;

LABURTE, C .

BRITISH JOURNAL OF DERMATOLOGY, 1990, 122 :85-93

[7]

GRIFFITHS CEM, 1989, BRIT J DERMATOL, V120, P253

[8] HYPERTRIGLYCERIDEMIA IN PATIENTS WITH PSORIASIS TREATED WITH CYCLOSPORINE [J].

GROSSMAN, RM ;

DELANEY, RJ ;

BRINTON, EA ;

CARTER, DM ;

GOTTLIEB, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (04) :648-651

[9] RELAPSE RATES IN MODERATELY SEVERE CHRONIC PSORIASIS TREATED WITH CYCLOSPORINE-A [J].

HIGGINS, E ;

MUNRO, C ;

MARKS, J ;

FRIEDMANN, PS ;

SHUSTER, S .

BRITISH JOURNAL OF DERMATOLOGY, 1989, 121 (01) :71-74

[10] EFFICACY AND SAFETY OF ORAL CYCLOSPORINE-A (CYA SANDIMMUN(R)) FOR LONG-TERM TREATMENT OF CHRONIC SEVERE PLAQUE PSORIASIS [J].

LABURTE, C ;

GROSSMAN, R ;

ABIRACHED, J ;

ABEYWICKRAMA, KH ;

DUBERTRET, L .

BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 (03) :366-375

← 1 2 →